Using multidisciplinary quality focus teams to develop 5-HT 3 antagonist guidelines

Formulary

Volumn 31, Issue 1, 1996, Pages 49-61

  Sanborn, Michael D ^a   Braman, Karen S ^a   Weinhold, Frank E ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DRONABINOL; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST;

ARTICLE; DOSE CALCULATION; DRUG COST; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; VOMITING;

EID: 0030056995     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Plosker GL and Goa KL Granisetron: A review of its pharmacological and therapeutic use as an antiemetic. Drugs 1994,42:805-24.
2. Gebbia V, et al Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994:74:1945-52
3. Noble A, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference. Eur J Cancer 1994;30A:1083-6
4. Navari R, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995,13.1242-8.
5. Hacking A Granisetron study group. Oral granisetron - simple and effective: a preliminary report. Eur J Cancer 1992;28A(suppl 1):S28-32
6. Heron J. et al Granisetron study group. Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994;5:579-84.